Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BG T19

Next Previous
Drug Profile

BG T19

Alternative Names: Anti-CD19 CAR-T - Guangzhou Bio-gene Technology; BG-19; BG-19C; BG-T19; CLL1 CAR-T Therapy - Guangzhou Bio-gene

Latest Information Update: 09 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Bio-gene Technology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Systemic lupus erythematosus
  • No development reported Acute myeloid leukaemia; Diffuse large B cell lymphoma

Most Recent Events

  • 19 Jun 2024 Phase-I/II clinical trials in Systemic lupus erythematosus (Treatment-experienced) in China (IV) (NCT06106906)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, In adolescents, In children, In infants, In neonates, Second-line therapy or greater) in China (Parenteral)
  • 30 Oct 2023 Guangzhou Bio-gene Technology and Wuhan Union Hospital plans phase-I/II trial for Systemic lupus erythematosus (Treatment-resistant) in December 2023 (IV, infusion) (NCT06106906)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top